Bellecapital International Ltd. Sells 118 Shares of Amgen Inc. (NASDAQ:AMGN)

Bellecapital International Ltd. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 3.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,219 shares of the medical research company’s stock after selling 118 shares during the period. Bellecapital International Ltd.’s holdings in Amgen were worth $927,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. OFI Invest Asset Management bought a new position in Amgen in the 3rd quarter worth about $26,000. Briaud Financial Planning Inc bought a new position in shares of Amgen during the third quarter valued at approximately $26,000. VisionPoint Advisory Group LLC bought a new position in shares of Amgen during the second quarter valued at approximately $28,000. Strategic Investment Solutions Inc. IL purchased a new stake in Amgen during the first quarter valued at approximately $28,000. Finally, Providence Capital Advisors LLC purchased a new stake in Amgen during the third quarter valued at approximately $30,000. 76.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on AMGN. Morgan Stanley decreased their price target on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Raymond James assumed coverage on shares of Amgen in a research note on Thursday. They set a “market perform” rating on the stock. Finally, StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $295.30.

Check Out Our Latest Analysis on AMGN

Amgen Price Performance

Shares of Amgen stock opened at $284.32 on Monday. The stock’s 50-day simple moving average is $289.21 and its 200-day simple moving average is $281.03. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a market capitalization of $152.37 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.69 and a beta of 0.58.

Amgen (NASDAQ:AMGNGet Free Report) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the business earned $4.09 EPS. As a group, analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.17%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.